Erykine Dosage/Direction for Use

Anemia Associated with Chronic Renal Failure: The recommended range for the starting dose of ERYKINE is 50 to 100 Unit/kg Three Times Weekly for adult patients. The dose of Erythropoietin should be reduced as the hematocrit approaches 36% or increase by more than 4 point in any 2-week period. Erytropoietin may be given either as an IV or SC injection. During therapy, haematological parameter should be monitored regularly. Dose adjustment should not be made more frequently than once a month, unless clinically indicated.
The haemoglobin concentration aimed for should be between 10 to 12 g/dL.
Treatment of Anemia In Cancer Patients on Chemotherapy: The recommended dose of ERYKINE for adults is 150 - 300 Units/kg, subcutaneously, three times weekly or 40,000 Units subcutaneously once in a week. Baseline endogenous serum Erythropoietin levels varied among patients with cancer related anemia. Treatment of patients with grossly elevated serum Erythropoietin levels (e.g. > 200 mUnits/mL) is not recommended. The hematocrit should be monitored on a weekly basis in patients receiving ERYKINE therapy until hematocrit becomes stable.
The haemoglobin concentration aimed for should be between 10 to 12 g/dL and it should not be exceeded.
Zidovudine-treated HIV-infected Patients: Starting Dose: Starting dose for adult patients with serum Erythropoietin levels ≤ 500 mUnits/mL who are receiving a dose of zidovudine ≤ 4,200 mg/week, the recommended starting dose of ERYKINE is 100 Units/kg as an intravenously or subcutaneously injection, 3 times weekly for 8 weeks. Prior to beginning ERYKINE therapy, it is recommended that the endogenous serum Erythropoietin level be determined (prior to transfusion). Available evidence suggests that patients receiving zidovudine with endogenous serum Erythropoietin levels > 500 mUnits/mL are unlikely to respond to therapy with Erythropoietin.
The haemoglobin concentration aimed for should be between 10 to 12 g/dL.
Reduction of Allogeneic Blood Transfusion in Surgery Patients: The recommended dose of ERYKINE is 300 Units/kg/day, subcutaneously, for 10 days before surgery, on the day of surgery, and for 4 days after surgery. Prior to initiating treatment with ERYKINE, a hemoglobin should be obtained to establish that it is > 10 to ≤ 13 g/dL. An alternate dose schedule is 600 Units/kg Erythropoietin, subcutaneously, in once weekly doses (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery. All patients should receive adequate iron supplementation. Iron supplementation should be initiated no later than the beginning of treatment with Erythropoietin and should continue throughout the course of therapy.
The haemoglobin concentration aimed for should be between 10 to 12 g/dL.